JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Boston Scientific Corp.

Closed

SectorHealthcare

101.13 -1.24

Overview

Share price change

24h

Current

Min

101.02

Max

101.42

Key metrics

By Trading Economics

Income

123M

795M

Sales

398M

5.1B

P/E

Sector Avg

59.135

37.461

Profit margin

15.708

Employees

53,000

EBITDA

155M

1.4B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+25.06% upside

Market Stats

By TradingEconomics

Market Cap

-4.6B

149B

Previous open

102.37

Previous close

101.13

News Sentiment

By Acuity

30%

70%

68 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Boston Scientific Corp. Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

22 paź 2025, 11:00 UTC

Earnings

Boston Scientific Raises Outlook on Continued Cardiovascular Growth

17 paź 2025, 11:43 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific to Buy Rest of Nalu Medical for $533 Million

23 lip 2025, 11:16 UTC

Earnings

Boston Sci 2Q Net Surges, Company Boosts '25 EPS View on Cardiology Demand

22 paź 2025, 10:32 UTC

Earnings

Boston Scientific Sees 4Q Organic Sales Up 11%-13% >BSX

22 paź 2025, 10:32 UTC

Earnings

Boston Scientific Sees 4Q Sales Up 14.5-16.5% >BSX

22 paź 2025, 10:31 UTC

Earnings

Boston Scientific Sees 2025 Organic Sales Up About 15.5% >BSX

22 paź 2025, 10:31 UTC

Earnings

Boston Scientific Sees 2025 Sales Up About 20% >BSX

22 paź 2025, 10:30 UTC

Earnings

Boston Scientific Sees FY Adj EPS $3.02-Adj EPS $3.04 >BSX

22 paź 2025, 10:30 UTC

Earnings

Boston Scientific 3Q Organic Sales Up 15.3% >BSX

22 paź 2025, 10:30 UTC

Earnings

Boston Scientific 3Q Adj EPS 75c >BSX

22 paź 2025, 10:30 UTC

Earnings

Boston Scientific Sees FY EPS $1.97-EPS $2.01 >BSX

22 paź 2025, 10:30 UTC

Earnings

Boston Scientific Sees 4Q EPS 48c-EPS 52c >BSX

22 paź 2025, 10:30 UTC

Earnings

Boston Scientific 3Q Sales $5.07B >BSX

22 paź 2025, 10:30 UTC

Earnings

Boston Scientific 3Q EPS 51c >BSX

22 paź 2025, 10:30 UTC

Earnings

Boston Scientific Sees 4Q Adj EPS 77c-Adj EPS 79c >BSX

17 paź 2025, 11:02 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific to Make Upfront Cash Payment of About $533 Million for Nalu Equity it Doesn't Already Own >BSX

17 paź 2025, 11:02 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific: Nalu Acquisition to Expand Neuromodulation Offerings for People Living With Chronic Pain >BSX

17 paź 2025, 11:01 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific: Nalu Medical Focused on Developing Minimally Invasive Solutions for Chronic Pain >BSX

17 paź 2025, 11:00 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific Announces Agreement To Acquire Nalu Medical, Inc. >BSX

9 wrz 2025, 12:58 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific to Buy Elutia's Bioenvelope Business for $88M

9 wrz 2025, 12:31 UTC

Acquisitions, Mergers, Takeovers

Elutia Announces Sale of BioEnvelope Business to Boston Scientific for $88M

23 lip 2025, 10:32 UTC

Earnings

Boston Scientific Sees 3Q Sales Up 17%-19%, Organic Sales Up 12%-14% >BSX

23 lip 2025, 10:31 UTC

Earnings

Boston Scientific Sees 2025 Sales Up 18%-19%, Organic Sales Up 14%-15% >BSX

23 lip 2025, 10:30 UTC

Earnings

Boston Scientific Sees FY EPS $1.89-EPS $1.93 >BSX

23 lip 2025, 10:30 UTC

Earnings

Boston Scientific 2Q Organic Sales Up 17.4% >BSX

23 lip 2025, 10:30 UTC

Earnings

Boston Scientific 2Q EPS 53c >BSX

23 lip 2025, 10:30 UTC

Earnings

Boston Scientific 2Q Sales $5.06B >BSX

23 lip 2025, 10:30 UTC

Earnings

Boston Scientific Sees 3Q Adj EPS 70c-Adj EPS 72c >BSX

23 lip 2025, 10:30 UTC

Earnings

Boston Scientific 2Q Adj EPS 75c >BSX

23 lip 2025, 10:30 UTC

Earnings

Boston Scientific Sees FY Adj EPS $2.95-Adj EPS $2.99 >BSX

Peer Comparison

Price change

Boston Scientific Corp. Forecast

Price Target

By TipRanks

25.06% upside

12 Months Forecast

Average 126.45 USD  25.06%

High 140 USD

Low 113 USD

Based on 24 Wall Street analysts offering 12 month price targets forBoston Scientific Corp. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

24 ratings

23

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

102.95 / 104.93Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

No Evidence

Sentiment

By Acuity

68 / 371 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
help-icon Live chat